Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE3
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-09-01
Study Completion Date
2026-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
NCT07091500
Obesity
Skeletal Muscle
RECRUITING
NA
Strength Training Response of Muscle in GLP-1 Users
NCT07104539
Muscle Mass
RECRUITING
NA
GLP-1s to Enhance Lasting Optimal Weight
NCT06861439
Obesity
ACTIVE_NOT_RECRUITING
PHASE4
Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
NCT05933499
Obesity
RECRUITING
PHASE2
Tirzepatide vs Liraglutide in Bone
NCT07094568
Obesity (Disorder)
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Obesity and type 2 diabetes remain at epidemic proportions in our country particularly in vulnerable populations such as elderly, and minority patients. Over the last 20 years, the use of incretin-based agents (Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) and Glucose dependent insulinotrophic polypeptide (GIP) to treat these disorders has offered unprecedented advances based on significant weight loss and reduction in major cardiovascular endpoints. Whilst weight loss provides a vital aspect for addressing obesity and type 2 diabetes, there are concerns associated with the quality of weight reduction.
The impact of losing weight on the musculoskeletal system has garnered recent attention in the lay press. Reported high-impact studies have reported excessive loss of skeletal muscle using GLP-1 RAs. The data regarding combined therapies (GLP-1 RA and GIP) suggested smaller loses. This preliminary data is based on using a surrogate marker (fat-free mass) determined by dual energy x-ray absorptiometry (DXA).
Recent reviews evaluating the impact that incretin-based agents have on fat-free-mass were found to be inconclusive based on high variability and multiple confounding factors. Assessing the impact that these agents have on the musculoskeletal system is now an important endeavor. (Aim 1-2) Diet-induced weight loss is also associated with bone loss, although little attention has focused on this potentially problematic outcome. In the CALERIE study, modest caloric restriction (15%) over two years led to weight loss and a 2% reduction in hip bone mineral density (BMD) among normal weight individuals. The mechanisms of weight loss-induced bone loss are unclear, although a drop in fat-free mass (which is composed of skeletal muscle, organs, water and connective tissues) principally muscle, such as occurs with the GLP1RAs, may predispose to injury, disability and bone loss. Another possibility is a mechanical form of skeletal adaptation to lower lean mass, through myokine mediated bone remodeling. However, significant trabecular bone loss in a non-weight bearing skeletal site occurs in mice as the investigators have shown in the mandible, from a 30% CR diet (Liu, personal communication). As such gravitational unloading due to weight loss is not solely responsible for deleterious skeletal changes. Despite the dramatic weight and lean mass loss from the GLP1 RAs, few clinical trials have focused on loss of muscle mass and fewer on any skeletal changes. In those that did, the results suggest equipoise for skeletal changes. There are no data on the skeletal effects from tirzepatide which can drive up to 25% weight loss. (Aim 1c) Also, it is unknown whether the addition of dietary modifications and resistance-based exercises impacts skeletal adaptation, muscle mass and bone loss. (Aim 2) Furthermore, there are inconsistent data in non-Hispanic Blacks with the GLP1 RAs because trial participation in under-represented populations has been poor. Hence, there is a major knowledge gap in our understanding the impact that a mixed GIP and GLP1RA, tirzepatide affects muscle and bone mass, particularly among underserved populations.
The wide-spread usage of GLP-1 related agents has not required formal recommendations regarding the use of exercises, specifically resistance-based exercises, or dietary protein optimization to address the potential for loss of fat-free mass or bone mineral density that has been suggested in studies evaluating body composition and bone density in subjects using these compounds. While the data for using such lifestyle interventions with diet and bariatric surgery have confirmed benefits in reducing loss of fat-free mass, the investigators know of only 1 published report using GLP-1 agents and exercise: Lundgren et al. found that in subjects using additional resistance-based exercise had a more favorable impact on sparing fat-free mass.
Additional gaps in our understanding remain despite the growing use and popularity of these agents. Additionally, patients with obesity and type 2 diabetes tend to develop ectopic fat within muscle (myosteatosis) that is not measured as part of fat free mass by DXA. It is posited that the major depot for acute loss of skeletal muscle from rapid weight loss may be from this portion of poor-quality lipid-rich tissue quelling major concerns. (Aim 2b) Aim 3, an explorative outcome, the investigators will determine if tirzepatide causes bone loss by measuring bone formation (P1NP) and bone resorption markers (NTx), if imbalanced skeletal remodeling is related to the change in total lean mass, muscle mass through reduced myokine (i.e., irisin) release, skeletal adaptation to weight change or another endocrine mechanism. Using a team science approach, the investigators will combine the expertise in metabolism and body composition of the PBRC group with skeletal expertise from MaineHealth to provide key insights into musculoskeletal effects from tirzepatide, a relatively new but often sought after drug for weight loss and type 2 diabetes. This supplement could also shed light on newer mechanisms of weight loss-induced bone loss and set the stage for a larger clinical trial.
The impact of losing weight on the musculoskeletal system has garnered recent attention in the lay press. Reported high-impact studies have reported excessive loss of skeletal muscle using GLP-1 RAs. The data regarding combined therapies (GLP-1 RA and GIP) suggested smaller loses. This preliminary data is based on using a surrogate marker (fat-free mass) determined by dual energy x-ray absorptiometry (DXA).
Recent reviews evaluating the impact that incretin-based agents have on fat-free-mass were found to be inconclusive based on high variability and multiple confounding factors. Assessing the impact that these agents have on the musculoskeletal system is now an important endeavor. (Aim 1-2) Diet-induced weight loss is also associated with bone loss, although little attention has focused on this potentially problematic outcome. In the CALERIE study, modest caloric restriction (15%) over two years led to weight loss and a 2% reduction in hip bone mineral density (BMD) among normal weight individuals. The mechanisms of weight loss-induced bone loss are unclear, although a drop in fat-free mass (which is composed of skeletal muscle, organs, water and connective tissues) principally muscle, such as occurs with the GLP1RAs, may predispose to injury, disability and bone loss. Another possibility is a mechanical form of skeletal adaptation to lower lean mass, through myokine mediated bone remodeling. However, significant trabecular bone loss in a non-weight bearing skeletal site occurs in mice as the investigators have shown in the mandible, from a 30% CR diet (Liu, personal communication). As such gravitational unloading due to weight loss is not solely responsible for deleterious skeletal changes. Despite the dramatic weight and lean mass loss from the GLP1 RAs, few clinical trials have focused on loss of muscle mass and fewer on any skeletal changes. In those that did, the results suggest equipoise for skeletal changes. There are no data on the skeletal effects from tirzepatide which can drive up to 25% weight loss. (Aim 1c) Also, it is unknown whether the addition of dietary modifications and resistance-based exercises impacts skeletal adaptation, muscle mass and bone loss. (Aim 2) Furthermore, there are inconsistent data in non-Hispanic Blacks with the GLP1 RAs because trial participation in under-represented populations has been poor. Hence, there is a major knowledge gap in our understanding the impact that a mixed GIP and GLP1RA, tirzepatide affects muscle and bone mass, particularly among underserved populations.
The wide-spread usage of GLP-1 related agents has not required formal recommendations regarding the use of exercises, specifically resistance-based exercises, or dietary protein optimization to address the potential for loss of fat-free mass or bone mineral density that has been suggested in studies evaluating body composition and bone density in subjects using these compounds. While the data for using such lifestyle interventions with diet and bariatric surgery have confirmed benefits in reducing loss of fat-free mass, the investigators know of only 1 published report using GLP-1 agents and exercise: Lundgren et al. found that in subjects using additional resistance-based exercise had a more favorable impact on sparing fat-free mass.
Additional gaps in our understanding remain despite the growing use and popularity of these agents. Additionally, patients with obesity and type 2 diabetes tend to develop ectopic fat within muscle (myosteatosis) that is not measured as part of fat free mass by DXA. It is posited that the major depot for acute loss of skeletal muscle from rapid weight loss may be from this portion of poor-quality lipid-rich tissue quelling major concerns. (Aim 2b) Aim 3, an explorative outcome, the investigators will determine if tirzepatide causes bone loss by measuring bone formation (P1NP) and bone resorption markers (NTx), if imbalanced skeletal remodeling is related to the change in total lean mass, muscle mass through reduced myokine (i.e., irisin) release, skeletal adaptation to weight change or another endocrine mechanism. Using a team science approach, the investigators will combine the expertise in metabolism and body composition of the PBRC group with skeletal expertise from MaineHealth to provide key insights into musculoskeletal effects from tirzepatide, a relatively new but often sought after drug for weight loss and type 2 diabetes. This supplement could also shed light on newer mechanisms of weight loss-induced bone loss and set the stage for a larger clinical trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Musculoskeletal Abnormalities
Obesity
Sarcopenic Obesity
Osteoporosis
Drug Effect
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
The investigators will enroll 25 subjects in each study arm. Both arms will involve treatment with a GLP-1 agonist (tirzepatide) for 5 months.
The intervention arm will use a lifestyle toolkit which includes protein supplements and resistance-based exercises.
The control group will use regular diet and exercise activities. Testing includes DXA and MRI body composition as well as lab tests to assess for muscle skeletal quality and physical fitness.
The intervention arm will use a lifestyle toolkit which includes protein supplements and resistance-based exercises.
The control group will use regular diet and exercise activities. Testing includes DXA and MRI body composition as well as lab tests to assess for muscle skeletal quality and physical fitness.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment/intervention group
Treatment with Tirzepatide for 5 months and lifestyle toolkit.
Group Type
EXPERIMENTAL
Tirzepatide
Intervention Type
DRUG
GLP-1 based treatment for obesity
Control/Placebo
Treatment with Tirzepatide for 5 months with regular diet and exercise.
Group Type
PLACEBO_COMPARATOR
Lifestyle toolkit
Intervention Type
BEHAVIORAL
2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tirzepatide
GLP-1 based treatment for obesity
Intervention Type
DRUG
Lifestyle toolkit
2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects will have a BMI between 30kg/m2
* 40kg/m2 (inclusive)
* Be between 18 and 50 years of age (inclusive).
* Non-Hispanic Black males and females will be enrolled at PBRC.
* Rural males and females will be enrolled at MaineHealth.
* Female subjects will be premenopausal.
* Females have had their last menstrual period less than 60 days before screening.
* Females have the absence of menopausal-associated vasomotor symptoms.
* All subjects must be able to use Lifestyle Toolkit as prescribed for intervention arm.
* 40kg/m2 (inclusive)
* Be between 18 and 50 years of age (inclusive).
* Non-Hispanic Black males and females will be enrolled at PBRC.
* Rural males and females will be enrolled at MaineHealth.
* Female subjects will be premenopausal.
* Females have had their last menstrual period less than 60 days before screening.
* Females have the absence of menopausal-associated vasomotor symptoms.
* All subjects must be able to use Lifestyle Toolkit as prescribed for intervention arm.
Exclusion Criteria
\- Males and females over the age of 50 years of age
* Menopausal females.
* Subjects on systemic corticosteroids or other agents known to increase loss of muscle and bone mass.
* Subjects who are on medications that increase or decrease weight status.
* Subjects having contraindications to tirzepatide in the package insert.
* Subjects with a history of malignancy other than non-melanoma skin cancer
* Subjects with known osteoporosis or are on osteoporosis therapies (gonadal hormones or hormone antagonists).
* Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.
* Subjects with a clinically significant hematologic abnormality, kidney disease, liver disease, or diabetes.
* Females of childbearing potential who do not agree to using an effective method of contraception during the study. Medically acceptable methods include oral contraceptive medication, an intrauterine device (IUD), an implantable contraceptive (such as Implanon), or a barrier method (such as condom or diaphragm with spermicide).
Injectable contraceptives such as Depo-Provera are a cause for exclusion in that they can cause bone loss.
Abstinence is acceptable, as is sexual activity exclusively with same sex partners.
Fertility Appreciation Based Methods (natural family planning) are also acceptable forms of addressing childbearing potential in all subjects. A urine pregnancy test (UPT) will be performed on all females of childbearing potential at the screening visit, 3 and 6 months.
* Unable to follow Lifestyle Toolkit as prescribed for intervention arm.
* Patient Health Questionnaire-9 (PHQ-9) Score equal to or greater than 15 (clinical depression).
* Adults who are unable to consent.
* Individuals who are not yet adults (infants, children and teenagers).
* Pregnant females.
* Incarcerated individuals.
* Contraindication to MRI - including but not limited to non-removable metallic or electronic implants, claustrophobia or other fear of confinement, inability to tolerate loud scanner noise, body weight greater than 500 pounds.
* Subjects with a baseline level of 25-OH vitamin D \<15 ng/ml will be excluded from the trial. The subject's physician will be notified, and the subject will be referred to their primary care physician.
* Any significant EKG abnormalities that are considered a risk for utilizing weight management therapies.
* Menopausal females.
* Subjects on systemic corticosteroids or other agents known to increase loss of muscle and bone mass.
* Subjects who are on medications that increase or decrease weight status.
* Subjects having contraindications to tirzepatide in the package insert.
* Subjects with a history of malignancy other than non-melanoma skin cancer
* Subjects with known osteoporosis or are on osteoporosis therapies (gonadal hormones or hormone antagonists).
* Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.
* Subjects with a clinically significant hematologic abnormality, kidney disease, liver disease, or diabetes.
* Females of childbearing potential who do not agree to using an effective method of contraception during the study. Medically acceptable methods include oral contraceptive medication, an intrauterine device (IUD), an implantable contraceptive (such as Implanon), or a barrier method (such as condom or diaphragm with spermicide).
Injectable contraceptives such as Depo-Provera are a cause for exclusion in that they can cause bone loss.
Abstinence is acceptable, as is sexual activity exclusively with same sex partners.
Fertility Appreciation Based Methods (natural family planning) are also acceptable forms of addressing childbearing potential in all subjects. A urine pregnancy test (UPT) will be performed on all females of childbearing potential at the screening visit, 3 and 6 months.
* Unable to follow Lifestyle Toolkit as prescribed for intervention arm.
* Patient Health Questionnaire-9 (PHQ-9) Score equal to or greater than 15 (clinical depression).
* Adults who are unable to consent.
* Individuals who are not yet adults (infants, children and teenagers).
* Pregnant females.
* Incarcerated individuals.
* Contraindication to MRI - including but not limited to non-removable metallic or electronic implants, claustrophobia or other fear of confinement, inability to tolerate loud scanner noise, body weight greater than 500 pounds.
* Subjects with a baseline level of 25-OH vitamin D \<15 ng/ml will be excluded from the trial. The subject's physician will be notified, and the subject will be referred to their primary care physician.
* Any significant EKG abnormalities that are considered a risk for utilizing weight management therapies.
Minimum Eligible Age
18 Years
Maximum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pennington Biomedical Research Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert Dubin
Principle Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Robert L. Dubin, MD
Baton Rouge, Louisiana, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism. 2000 Apr;49(4):467-72. doi: 10.1016/s0026-0495(00)80010-4.
Reference Type
BACKGROUND
Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, Svane MS, Bandholm T, Bojsen-Moller KN, Blond MB, Jensen JB, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021 May 6;384(18):1719-1730. doi: 10.1056/NEJMoa2028198.
Reference Type
BACKGROUND
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
Reference Type
BACKGROUND
Dubin RL, Heymsfield SB, Ravussin E, Greenway FL. Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps. Diabetes Obes Metab. 2024 Dec;26(12):5503-5518. doi: 10.1111/dom.15913. Epub 2024 Sep 30.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PBRC 2024-031
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy
NCT06885736
NOT_YET_RECRUITING
NA
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
NCT02718950
UNKNOWN
PHASE3
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
NCT01557166
COMPLETED
PHASE3
Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
NCT02928679
COMPLETED
PHASE4
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
NCT03041792
COMPLETED
PHASE1
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
NCT05779644
UNKNOWN
NA
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
NCT06801015
ACTIVE_NOT_RECRUITING
PHASE4
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
NCT07092605
ENROLLING_BY_INVITATION
EARLY_PHASE1
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
NCT05064735
COMPLETED
PHASE3
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
NCT04657016
COMPLETED
PHASE3
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
NCT05419726
RECRUITING
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
NCT07225816
RECRUITING
PHASE1
Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker
NCT04408586
COMPLETED
PHASE4
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
NCT06824051
COMPLETED
PHASE1
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
NCT05412004
COMPLETED
PHASE3
Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance
NCT02928614
COMPLETED
PHASE4
Anti-obesity Pharmacotherapy and Inflammation
NCT05756764
ACTIVE_NOT_RECRUITING
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
NCT03671733
UNKNOWN
PHASE3
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
NCT06737042
NOT_YET_RECRUITING
PHASE2
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
NCT04081337
COMPLETED
PHASE1
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
NCT06445075
COMPLETED
PHASE2
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT05872620
COMPLETED
PHASE3
Weight Loss and Physical Activity in Overweight/Obese Individuals With Knee Osteoarthritis
NCT02910544
COMPLETED
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
NCT06500429
COMPLETED
PHASE2
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548
ACTIVE_NOT_RECRUITING
PHASE3